Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback